Impact of Energy Density on Energy Intake During Bed Rest
- Conditions
- Bed RestSpace Analogue
- Registration Number
- NCT06571877
- Lead Sponsor
- University Hospital Tuebingen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria:<br><br> - Physically and mentally healthy test subjects that declare their willingness to<br> participate in the entire study and successfully pass the psychological and medical<br> screening<br><br> - Aged between 24 and 55 years<br><br> - Body mass index between 18 to 28 kg/m2<br><br> - Body height between 153 to 190 cm (+/- 2 cm)<br><br> - Signed informed consent<br><br> - Demonstrable medical insurance and official certificate of absence of criminal<br> record<br><br> - No less than 2 SD below the average normal bone mineral density (measured by<br> dual-energy x-ray absorptiometry) for hip and lumbar spine (i.e., mean peak bone<br> mineral density of Caucasian, sex-matched young adults) denoted by T-score (T-score<br> > -2)<br><br> - Demonstrable dentist certificate<br><br> - Hormonal contraception for female participants is allowed, but details<br> (manufacturer, doses, dates) must be reported<br><br>Exclusion Criteria:<br><br>Candidate subject exclusion criteria for the study will include the following:<br><br> - Any infectious, genetic, autoimmune, endocrinological, hematological,<br> cardiovascular, lung, gastroenterological, kidney, rheumatic, muscle, bone,<br> orthopedic, dermatological, gynecological, urological, ophthalmological,<br> otorhinolaryngological, neurological or psychiatric disease (see at the end of<br> document; a) that precludes a safe participation in the study or might significantly<br> impact scientific results of the study according to the study physician<br><br> - Drug, medication or alcohol abuse (regular consumption of more than 30 g<br> alcohol/day)<br><br> - Smoker within 6 months prior to enrollment<br><br> - Any long-term medication use that might significantly impact scientific results of<br> the study (for instance bisphosphonate therapy, anti-hypertensives,<br> gastro-esophageal reflux).<br><br>Special dietary requests, that cannot be provided by the project team (e.g. vegan,<br>vegetarian or other ineligible diet)<br><br> - Claustrophobia<br><br> - Increased intraocular pressure<br><br> - Hyperopia / Myopia > +/- 5.0 Diopters<br><br> - Astigmatism > 3 Diopters<br><br> - History of laser surgery of the eye, glaucoma and retinal surgery<br><br> - Any ocular condition that would significantly impact visual function<br><br> - Significant chronic gastro-esophageal reflux precluding a safe participation in the<br> study<br><br> - Clinically relevant allergy (e.g. requirement to carry a stand-by emergency<br> injection), that precludes a safe participation in the study<br><br> - History of chronic back complaints, that precludes a safe participation in the study<br><br> - History of kidney stones<br><br> - Anemia: Hemoglobin under normal values (see at the end of document; b). (Normal<br> values of Hemoglobin for men: 13.0-17.5 g/dl; women 12.0-16.0 g/dl)<br><br> - Elevated risk of thrombosis (see at the end of document; c)<br><br> - Inability to successfully complete a 10-minute upright posture test without<br> clinically relevant orthostatic symptoms<br><br> - Current or history of hemorrhagic diathesis or coagulations disorders<br><br> - History of spinal cord disease, including radiculopathy, myelopathy, or neuropathy<br><br> - History of disorders affecting CSF circulation (i.e. hydrocephalus, idiopathic<br> intracranial hypertension) History of more than one depressive episode and/or<br> history of a severe depressive episode, such as requiring inpatient or intensive<br> outpatient treatment<br><br> - Known chronic tinnitus<br><br> - Hearing loss (bi-lateral or one-sided) precluding successful participation in the<br> study<br><br> - Female candidate is pregnant or breast-feeding<br><br> - Female candidate is in menopause or post-menopause, unless on hormone replacement<br> therapy (but not treated with bisphosphonates or anti-resorptives)<br><br> - Female candidate stopped hormonal contraception medication up to 3 months prior to<br> study start<br><br> - Metal implants (or objects like metallic slivers in the eyes, or bullets or shrapnel<br> in the body) or other kinds of bone synthesis materials, implanted medical devices,<br> tattoos or permanent make-up incompatible with MRI<br><br> - Participation in a (clinical) study within the last 3 months before start of this<br> study that significantly confounds participation in the study Any other condition<br> which makes the test subject unsuitable for study inclusion in the opinion of the<br> project team<br><br>Explanations to exclusion criteria (a-c)<br><br> 1. History of single episode of prolonged grief or mild depression with no symptoms in<br> the 12 months prior to study start is acceptable<br><br> 2. Normal values from: https://www.lab-quade.de/leistungen/?idLoc=1<br><br> 3. A thrombosis risk stratification will be conducted according to clinical standards:<br> in the anamnesis, the subject will be extensively questioned for thrombosis risk<br> factors and assessed by means of specific analytical laboratory methods for<br> assessing thrombosis risk using thrombophilia screening
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Energy intake in kcal
- Secondary Outcome Measures
Name Time Method Amount of food intake in g;Composite appetite score measured by 10 cm visual analogue scales (VAS);Visual analogue scale for perception of portion size;Emotional response;Number of participants assigned to countermeasures for consequences of long-term bed rest